TABLE 2

Description of scenario analyses

NumberScenarioStarting age yearsDescriptionTreatment duration
1Base-case25There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, there is 50% efficacy of ivacaftorLifetime
2Optimistic25There is full efficacy of ivacaftor though lifetime horizonLifetime
3Intermediate25There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, there is 66% efficacy of ivacaftorLifetime
4Conservative25There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, patients stop the treatment2 years
56-year-old6There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, there is 50% efficacy of ivacaftor; the starting age of the cohort is 6 yearsLifetime
69-year-old9There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, there is 50% efficacy of ivacaftor; the starting age of the cohort is 9 yearsLifetime
712-year-old12There is full efficacy of ivacaftor within first 2 years of treatment; after 2 years, there is 50% efficacy of ivacaftor; the starting age of the cohort is 12 yearsLifetime